BTK Protein (Bruton's Tyrosine Kinase) <div class="infobox infobox-protein">
Overview BTK (Bruton's Tyrosine Kinase) is a non-receptor tyrosine kinase belonging to the Tec family. The [BTK](/genes/btk) gene encodes a 659-amino acid protein originally characterized for its essential role in B cell receptor signaling and B cell development. Recently, BTK has emerged as a significant player in neuroinflammation and neurodegenerative diseases.
Structure BTK contains multiple functional domains:
...
BTK Protein (Bruton's Tyrosine Kinase) <div class="infobox infobox-protein">
Overview BTK (Bruton's Tyrosine Kinase) is a non-receptor tyrosine kinase belonging to the Tec family. The [BTK](/genes/btk) gene encodes a 659-amino acid protein originally characterized for its essential role in B cell receptor signaling and B cell development. Recently, BTK has emerged as a significant player in neuroinflammation and neurodegenerative diseases.
Structure BTK contains multiple functional domains:
| Domain | Position | Function |
Biological Function
B Cell Receptor Signaling BTK is essential for B cell development:
Pre-BCR signaling in pro-B cells
Mature BCR signaling
B cell survival and proliferation
Antibody production
Signaling Pathways BTK activates multiple downstream pathways:
PLCγ2 : Calcium signaling, NFAT activationPI3K/AKT : Cell survival signaling[NF-κB](/entities/nf-kb) : Transcriptional activationMAPK/ERK : Cell proliferationNon-Immune Functions BTK is expressed in:
Macrophages : Inflammatory cytokine production[Microglia](/cell-types/microglia-neuroinflammation) : Brain immune cells[Neurons](/entities/neurons) : Developmental roles[Astrocytes](/entities/astrocytes) : Glial functionRole in Neurodegeneration
Alzheimer's Disease BTK in microglia contributes to AD pathogenesis:
Neuroinflammation : BTK regulates pro-inflammatory cytokine productionMicroglial activation : BTK inhibitors reduce microglial activationAmyloid clearance : Alters phagocytic activityDisease progression : BTK activity correlates with pathology
Parkinson's Disease
Microglial activation : BTK in dopaminergic degenerationNeuroinflammation : Chronic inflammation in PD brainTherapeutic target : BTK inhibitors in clinical trials for PDMultiple Sclerosis BTK inhibitors show promise:
Reduces relapse rates
Decreases new lesions
Suppresses microglial activation
Therapeutic Implications
BTK Inhibitors FDA-approved and experimental BTK inhibitors:
| Drug | Status | Indication |
Neurodegeneration Trials BTK inhibitors in development for:
Alzheimer's disease (Phase 2)
Parkinson's disease (Phase 1/2)
Multiple sclerosis (Phase 3)
See Also
External Links
[GeneCards: BTK](https://www.genecards.org/cgi-bin/carddisp.pl?gene=BTK)
BTK in Neuroinflammation Microglial BTK contributes to:
Pro-inflammatory cytokine release : TNF-alpha, IL-1beta, IL-6Chemokine production : MCP-1, MIP-1alphaCell surface marker expression : MHC class II, CD86 antigen presentation : T cell activationClinical Trials Current BTK inhibitor trials for neurodegeneration:
| Trial | Compound | Phase | Indication |
Safety Considerations BTK inhibitor side effects:
Bleeding risk : On-target platelet dysfunctionInfections : ImmunosuppressionAtrial fibrillation : Cardiovascular effectsCytopenias : Blood count abnormalitiesReferences
[Klein et al., BTK in neuroinflammation (2020) (2020)](https://doi.org/10.1038/s41582-020-0339-3)
[Mancini et al., BTK inhibitors in AD (2019) (2019)](https://doi.org/10.1016/j.tins.2019.02.007)
[Dorward et al., Microglial BTK (2021) (2021)](https://doi.org/10.1038/s41586-021-03526-y) Show full description